ACCESS TO ADVANCED HEALTH INSTITUTE

Rna vaccines - rna vaccines have been shown to be critical tools for combatting pandemics and have been safely administered to billions of people across the globe. Aahi's rna vaccine platform is distinct from existing licensed rna vaccines in that it is based on a self-amplifying rna technology and delivered by a flexible nanostructured lipid carrier. Together, these features mean that the vaccine could be stockpiled for years, delivered at room temperature, and more rapidly manufactured to address future pandemics. Aahi scientists are advancing rna vaccines against covid-19, influenza, yellow fever, zika, chikungunya, and hiv, and adapting the platform to be delivered by nasal spray or directly administered into tumors.

Process and product development - modern vaccines are increasingly complex and their design needs to be tailored to specific target product profiles to ensure practical accessibility. Sustainable sourcing of raw materials, streamlined manufacturing methods, and temperature stability are critically important to enable vaccines for global health applications in resource-limited settings. Alternative routes of administration, such as intranasal delivery, not only may best be suited to fight respiratory pathogens but also help to address vaccine hesitancy and to increase vaccine uptake. Aahi scientists are world-experts at developing processes and methods to advance novel products that meet the needs of vaccine developers both within aahi and externally among the dozens of academic, non-profit, and commercial partners.